NCT04677153

Rapid HCV Treatment Access for Persons Who Use Drugs

Rapid HCV Test and Treat to Increase HCV Treatment Uptake Among People Who Use Drugs

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 198 (actual)
• Sponsor: Johns Hopkins University · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This study is being done to compare two strategies to deliver HCV treatment to persons with hepatitis C virus (HCV) who also use drugs and are participating in an outpatient opioid treatment program (OTP). Participants will be randomized into one of two treatment groups: 1. Test and treat plus peer-mentors: This treatment group will be offered 8 weeks of glecaprevir/pibrentasvir (an FDA approved HCV treatment) within days of HCV diagnosis at the OTP. Participants in this group will receive treatment adherence support from a peer-mentor who is someone who has been cured of HCV infection. 2. Standard of care HCV treatment referral: This treatment group will be referred to an offsite HCV treatment location. This is the usual care for anyone who tests positive for HCV at the OTP who is not participating in this study.

Conditions

• Hepatitis C Virus Infection, Response to Therapy of

Interventions

Type	Name	Description
OTHER	Test and treat plus peer mentors	Rapid start of HCV treatment at OTP within days of HCV diagnosis. Participants will receive 8 weeks of glecaprevir/pibrentasvir and will work with a peer mentor during and after treatment.
OTHER	Usual care	Participants are referred to another location for HCV treatment.

Timeline

• Start date: 2021-08-06
• Primary completion: 2024-02-23
• Completion: 2024-09-23
• First posted: 2020-12-21
• Last updated: 2026-04-13
• Results posted: 2026-04-13

Locations

4 sites across 2 countries: United States, Canada